The Indian central government has taken serious action over health concerns linked to a group of widely used acidity and gas relief medicines. These include popular brands such as Rantac, Zinetac, and Aciloc, all of which contain the drug Ranitidine.
Ranitidine belongs to the class of medications called Histamine-2 blockers. It is commonly prescribed to treat acidity, indigestion, stomach pain, gastric ulcers, and gastroesophageal reflux disease (GERD). For years, these drugs have been a go-to remedy for millions in India.
However, long-standing concerns about the possible link between Ranitidine and cancer have now prompted the government to launch a nationwide investigation. The Central Drugs Standard Control Organization (CDSCO) has issued strict orders to all state and union territory drug regulators.
The primary focus of the investigation is to examine the presence of N-Nitrosodimethylamine (NDMA) — a chemical impurity believed to be a potential cancer-causing agent. Authorities are instructed to check how much of this substance is present in Ranitidine-based drugs.
Additionally, regulators have been asked to ensure that Ranitidine products are not being stored on pharmacy shelves for extended periods, which could lead to chemical breakdown and contamination over time.
The issue first gained global attention in 2019, when the U.S. Food and Drug Administration (FDA) reported traces of NDMA in Ranitidine medicines. The agency raised alarms that the drug might pose a cancer risk if consumed regularly or in high doses.
Following this, the U.S. banned the sale of Ranitidine-based drugs in 2020. The decision created ripples across the world, including in India, where millions depend on these medicines for routine digestive issues.
In December of last year, the CDSCO formed an expert panel to conduct a detailed review of Ranitidine. The committee submitted its findings recently, prompting the new wave of regulatory action across Indian states.
The Indian authorities are not banning the medicine yet, but the investigation aims to determine the safety levels and whether the drug continues to meet current health standards. Depending on findings, further regulatory decisions may follow.
The core concern lies in the NDMA content found in Ranitidine. NDMA is classified as a probable human carcinogen. Studies suggest that prolonged exposure can lead to cancers in the stomach, esophagus, bladder, and other parts of the digestive system.
Several global studies have observed that NDMA levels in Ranitidine may increase when the drug is stored at higher temperatures or for longer durations. This is another reason regulators are checking how these drugs are stored in India.
Doctors in India have often prescribed Ranitidine to patients with GERD, stomach ulcers, and acid reflux, considering it a safe option. But now, many are becoming cautious and exploring alternative medications that do not carry the same level of risk.
Pharmaceutical companies are also under scrutiny. Manufacturers have been instructed to test their products for NDMA levels and report their findings to the CDSCO. This transparency is seen as a vital step toward ensuring public safety.
Some hospitals and doctors have already started phasing out Ranitidine from their prescriptions, replacing it with newer acid-reducing medications like Famotidine or Esomeprazole, which are not linked to similar cancer concerns.
The government’s action is viewed as a preventive measure to avoid a large-scale health crisis. Officials say public awareness and early investigation can help avoid risks before they escalate into serious problems.
Health experts are also urging consumers to avoid panic. They recommend that anyone currently taking Ranitidine should consult their doctor before stopping or changing their medication. Self-medication or abrupt discontinuation can also be harmful.
At the same time, patients are being encouraged to check medicine labels carefully and to stay informed about updates issued by health authorities regarding Ranitidine and its alternatives.
This development is a reminder of how important drug safety monitoring is in a country as large and diverse as India, where millions rely on over-the-counter medications for daily ailments.
The CDSCO’s investigation will include random sampling of Ranitidine products from different manufacturers and retail outlets across India. The samples will be tested in accredited laboratories for NDMA levels.
The results of this investigation will help determine the future of Ranitidine in India. If high levels of NDMA are found, the government may decide to impose stricter regulations or even a nationwide ban, similar to the U.S.
Until then, doctors, patients, and pharmacists are being advised to exercise caution and follow medical advice when using or prescribing Ranitidine-based drugs.
